Cardiac amyloidosis has a poor prognosis, with a median survival of approximately 6 months once symptoms develop. This patient had a markedly improved quality of life with cardiac transplantation. We would suggest that with refinement of pretransplant chemotherapy, prolonged survival may be possible in carefully selected cases.